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Mohamed L. Sorror1,2In this issue of Biology of Blood and Marrow
Transplantation, colleagues from Dresden, Germany,
reported on the prognostic impact of the hematopoi-
etic cell transplantation-specific comorbidity index
(HCT-CI) among patients diagnosed with acute
myeloid leukemia and treated with allogeneic hemato-
poietic cell transplantation (HCT) using at least 9
different types of conditioning regimens. The authors
elected to stratify patients into HCT-CI scores of
0 (5%), 1-2 (21%), and $3 (74%). Multiple analyses
failed to show any statistically significant association
between the HCT-CI scores and nonrelapse mortality
(NRM) or overall survival (OS) [1].
TheHCT-CI was found to be associated with out-
comes in numerous previous studies [2]. A smaller
number of studies with issues related to sample size
or lack of sufficient comorbidity data disagreed [2].
The Dresden study is the first with a fair sample size
of patients and complete comorbidity data that showed
lack of association between HCT-CI scores and
outcomes. The benefit of good sample size was
relatively offset by multiplicity of regimens and the
skewed distribution of patients among risk groups.
Although the authors’ suggestion that differences in
socioeconomic factors among institutions might, in
part, explain the discordant findings is plausible,
other reasons seem to play a more prominent role in
this study.
The 2 points of concern are the inaccurate evalua-
tion of relevant comorbidities and the unbalanced
categorization of patients into risk groups despite pre-
vious recommendations [3]. The paper included unex-
pectedly high prevalence of heart valve disease, hepatic
comorbidity, and infections. Of note, the HCT-CI1Fred Hutchinson Cancer Research Center; and 2Univer-
Washington, Seattle, Washington.
isclosure: See Acknowledgments on page 1722.
dence and reprints requests: Mohamed L. Sorror, MD,
Fred Hutchinson Cancer Research Center, 1100 Fairview
e N., D1-100, P.O. Box 19024, Seattle, WA 98109-1024.
il: msorror@fhcrc.org).
ctober 9, 2011; accepted October 17, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.10.026was modified based on the Charlson comorbidity
index, and both indices have distinctive definitions of
the magnitude of comorbidities that are relevant to
prediction of mortality [4,5]. Heart valve disease
indicates significant valve abnormality [4] and not
any degree of valve regurgitation constitutes a disease.
The period during which the hepatic function
tests were evaluated in the Dresden paper is not sup-
ported by a criterion in the HCT-CI. Further, it is
not clear if pretransplant infections met the criteria
for scoring. Likewise, other comorbidities might
have been unrecognizably underestimated. The au-
thors attempted to overcome these 2 points of concern
by either assessing the index as a numerical variable or
excluding some comorbidity data. Each of the 2 ap-
proaches is of limited utility to resolving the underly-
ing problems.
TheHCT-CI introduced new definitions for some
comorbidities and relied on the Charlson comorbidity
index definitions for others [4,5]. A degree of flexibility
was allowed in interpreting those definitions for 2 rea-
sons. One is the possibility that individual patients
have a range of clinical presentations of a single co-
morbidity, whose relevance could best be decided on
by an experienced evaluator. The second is the concern
that a restriction in the range of comorbidity defini-
tions might work against the validity of the index. In
fact, further restriction in comorbidity definitions
could be a double-edge sword improving reliability
but reducing validity of a measure [6].
The performance of the HCT-CI has been under
extensive evaluation. A study comprising 5 institutions
was initiated in 2007 to investigate the reliability and
validity of the index across institutions. Among a sam-
ple size of 2523 patients constituting the largest cross-
validation study of the HCT-CI yet, patients with
scores of 0, 1-2, and $3 had 2-year NRM incidences
of 14%, 23%, and 39%, respectively (P\ .0001) and
OS rates of 74%, 61%, and 39%, respectively (P\
.0001) [7]. Pretransplant characteristics were different
among institutions. In proportional hazard models
adjusted for all covariates, increased HCT-CI scores
were associated with increased hazard ratios (HR) for
NRM and OS consistently across all 5 institutions.
These increases were highly statistically significant
except for the institution with the smallest sample1721
1722 Biol Blood Marrow Transplant 17:1721-1724, 2011M. L. Sorrorsize (n 5 159), highlighting the importance of sample
size in validation studies. Interestingly, patients
with given comorbidity scores faired differently across
institutions, probably because of differences in institu-
tional performances in managing transplanted patients
because an institutional effect was detected for NRM
(P 5 .001) and OS (P\ .001).
A single investigator evaluated comorbidities in
this multicenter study to ensure consistent pattern of
comorbidity coding. Then, 80 patients were scored
by another evaluator with no prior experience in co-
morbidity coding. The weighted kappa statistics (KS)
between the 2 evaluators was 0.59 and the figures
were even lower when scores from both evaluators
were comapred with those assigned by multiple
evaluators in the clinic. These findings underlined
the need for a comprehensive education program to
teach transplant and oncology physicians how to eval-
uate comorbidities. The foundation of this education
program has already been laid down. Training of the
previous single evaluator improved the KS to 0.78,
which compares favorably to a range of 0.6-0.8 re-
ported for comorbidity measures in practice [8]. Com-
pletion of this Education Program is in progress with 2
goals: 1) to improve the rate of agreement in comor-
bidity coding beyond KS of 0.8 and, while 2) retaining
a degree of flexibility in the definitions of comorbid-
ities that would ensure world-wide validity of the index
in outcome prediction.
TheDresden paper brought up some other contro-
versial points. First, interpreting the impacts of
predictive models should not be limited to the digits
of a P-value, because a P-value relies, in part, on the
number of patients in the overall and subset groups.
Assessment of the direction of the HR is important,
taking into account other covariates, homogeneity of
the data, and sample size. Second, as eluded to previ-
ously [3], no comorbidity measure is limited by an
absolute criteria for score categorization. Squeezing
three-fourths of a patient population into a single risk
group limits both the clinical application and the statis-
tical evaluation of the data. The term ‘‘flexible’’ HCT-
CI is incorrect and implies the presence of a different
model. Categorization of comorbidity risk groups
should be based on the clinical situation including
regimen intensity, prevalence of comorbidities, and
other factors. Third, we have demonstrated previously
that the integer not the exact weights of the HCT-CI
were associated with accurate prediction of HCT
outcomes, not to mention being simpler [3]. Fourth,
authorities should refrain from denying access to
HCT based solely on the HCT-CI scores, not because
of doubts in the validity of the index but because
no scores could yet be associated with an absolute
lack of benefit from HCT [9]. Observational studies
incorporating the HCT-CI with other risk factorsmight answer the question: who should not be offered
allogeneic HCT?
For decades, age has been the main patient-specific
decision-making tool forHCT.However, agehasnever
been a consistently valid predictor of HCT outcomes
[2]. The introduction of comorbidity evaluation has
revolutionized the field of outcome analysis of HCT.
Recent studies have shown that chronological age is of
limited or no value in outcome prediction once comor-
bidities are taken into account [10-12]. Comorbidity
evaluation is emerging rapidly as the most important
predictor ofHCToutcomes and an approach for future
individualization ofmedical care; however, this promis-
ing advancement in the field comes at a high price. The
practice of comorbidity assessment is still in the devel-
opmental stage, and the accumulated evidence so far
suggests it is a challenging undertaking for transplant
physicians and data managers. Although efforts to
achieve world-wide accurate and valid comorbidity as-
sessment continue, single institutions are required to
prepare their own teams of personnel trained and spe-
cialized in comorbidity evaluation.ACKNOWLEDGMENTS
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Transplantation Should Be Considered a Standard of
Care for Older Patients with Acute Myeloid Leukemia
Richard ChamplinAcute myeloid leukemia (AML) is primarily a dis-
ease of older people with a median age greater than
65 years. The treatment of AML in elderly patients
remains a major challenge. Older patients are more
likely to have high-risk cytogenetic abnormalities, and
age itself confers a poor prognosis. There has been little
progress with standard forms of chemotherapy [1-3].
Allogeneic stem cell transplantation (SCT) were
originally developed as a means of delivering high-dose
myeloablative chemotherapy or radiationwith the trans-
plant to provide hematologic recovery after the myeloa-
blative therapy [4]. This approach is associated with
considerable toxicity, and could only be performed in
relatively young patients in excellent general medical
condition. We have come to appreciate that much of
the benefit is derived from the graft-versus-leukemia
effect mediated by donor immune cells [5,6]. This reali-
zation has supported the development of reduced-
intensity or nonmyeloablative preparative regimens
involving lower doses of chemotherapy and/or total-
body radiation, which are sufficiently immunosuppres-
sive to prevent rejection and allow development of the
graft-versus-leukemia effect [7-10]. These reduced-
intensity regimens allow treatment of older or medically
infirm patients whowere not previously eligible for allo-geneic stem cell transplantation [11]. Reduced-intensity
regimens may be associated with a higher risk of relapse
compared with myeloablative conditioning, but
leukemia-free survival is similar in most studies [12,13].
Patients up to age75 yearshavebeen treatedwith this ap-
proach. Similar results are reportedwithmatched related
or unrelated donors [14,15].
A number of studies have shown promising results
of reduced-intensity transplants in patients with AML.
In this issue, Farag et al. [16] evaluate the results of
treatment for patients age 60 to 70 years, comparing
the results of reduced-intensity allogeneic transplanta-
tions reported to the Center for International Blood
andMarrowTransplant Research with patients receiv-
ing standard chemotherapy on Cancer and Leukemia
Group B protocols. The 2 groups had similar patients
characteristics and prognostic factors. The transplant
recipients were slightly younger than the chemother-
apy group. Patients receiving allogeneic HCT had
a significantly lower risk of relapse (32% versus 81%
at 3 years; P\ .001), and longer leukemia-free survival
(32% versus 15% at 3 years; P\ .001). Allogeneic stem
cell transplantation is a high-risk procedure, and as ex-
pected, there was a higher risk of nonrelapse mortality
at 3 years (36% versus 4%; P\ .001). Overall survival
was 37% versus 25% at 3 years (P 5 .08).
One limitation of this type of analysis is the effect of
patient selection. Older patients undergoing SCT are
selected to be in good enough medical condition to
undergo SCT and are a self-selected, highly motivated
group of patients. Allogeneic SCT involves a major
commitment on the part of the patient, requiring close
medical monitoring for at least several months. It
frequently requires patients and their caregivers to
relocate temporarily to another city to be near the trans-
plant center.Allogeneichematopoietic transplantation is
